ResearcherAssistance Publique – Hôpitaux de ParisActive in the last 2 years
Émilie Soularue
Matched on ORCID iD 0000-0003-3223-5720; OpenAlex author ID A5050101046. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 32
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 4
- Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
- Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
- Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Last author DOI 10.1016/j.clinre.2020.101607↗
- Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter … Co-author DOI 10.1016/j.clinre.2019.08.009↗
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Isabelle Trouilloud · 4 shared papers, 2020–2025 · strength 0.48
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. DOI 10.21037/jgo-22-946↗
- Paper Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. DOI 10.1016/j.clinre.2020.101607↗
- Jean‐Baptiste Bachet · 2 shared papers, 2023–2025 · strength 0.28
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. DOI 10.21037/jgo-22-946↗
- Pascal R. Hammel · 2 shared papers, 2021–2025 · strength 0.27
- Romain Coriat · 2 shared papers, 2021–2025 · strength 0.27
- Anne‐Laure Pointet · 2 shared papers, 2020–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic… DOI 10.1016/j.clinre.2019.08.009↗
- Dominique Béchade · 2 shared papers, 2020–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic… DOI 10.1016/j.clinre.2019.08.009↗
- Julien Taı̈eb · 2 shared papers, 2020–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic… DOI 10.1016/j.clinre.2019.08.009↗
- Simon Pernot · 2 shared papers, 2020–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic… DOI 10.1016/j.clinre.2019.08.009↗
- Nicolas Williet · 2 shared papers, 2020–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic… DOI 10.1016/j.clinre.2019.08.009↗
- David Tougeron · 2 shared papers, 2020–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic… DOI 10.1016/j.clinre.2019.08.009↗
- Raëf Abdallah · 1 shared paper, 2025 · strength 0.16
- Alix Portal · 1 shared paper, 2025 · strength 0.16
- Franck Bonnetain · 1 shared paper, 2025 · strength 0.16
- Laëtitia Dahan · 1 shared paper, 2025 · strength 0.16
- Jean–Marc Phelip · 1 shared paper, 2025 · strength 0.16
- Camille Evrard · 1 shared paper, 2025 · strength 0.16
- Lysiane Marthey · 1 shared paper, 2025 · strength 0.16
- Sylvain Manfrédi · 1 shared paper, 2023 · strength 0.12
- Côme Lepage · 1 shared paper, 2023 · strength 0.12
- Noelle K. LoConte · 1 shared paper, 2023 · strength 0.12
- Jerome F. Cros · 1 shared paper, 2023 · strength 0.12
- David Piquemal · 1 shared paper, 2023 · strength 0.12
- Christophe Tournigand · 1 shared paper, 2023 · strength 0.12
- Emmanuelle Kempf · 1 shared paper, 2023 · strength 0.12
- Cindy Canivet · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.